Trial · NCT01866930
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) | Cohort A: HCV GT-2 or GT-3 | 88 | Participants | ||
| Number of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) | Cohort B: HCV GT-1 or GT-4 | 149 | Participants | ||
| Number of Participants With Rapid Virologic Response (RVR) and Extended Rapid Virologic Response (eRVR) | Cohort A: HCV GT-2 or GT-3 | RVR | 82 | Participants | |
| Number of Participants With Rapid Virologic Response (RVR) and Extended Rapid Virologic Response (eRVR) | Cohort B: HCV GT-1 or GT-4 | RVR | 149 | Participants | |
| Number of Participants With Rapid Virologic Response (RVR) and Extended Rapid Virologic Response (eRVR) | Cohort A: HCV GT-2 or GT-3 | eRVR | 80 | Participants | |
| Number of Participants With Rapid Virologic Response (RVR) and Extended Rapid Virologic Response (eRVR) | Cohort B: HCV GT-1 or GT-4 | eRVR | 138 | Participants | |
| Number of Participants With Treatment Emergent Cytopenic Abnormalities | Cohort A: HCV GT-2 or GT-3 | 4 | Participants | ||
| Number of Participants With Treatment Emergent Cytopenic Abnormalities | Cohort B: HCV GT-1 or GT-4 | 15 | Participants | ||
| Number of Participants With On-treatment IFN-associated Flu-like or Musculoskeletal Symptoms | Cohort A: HCV GT-2 or GT-3 | Musculoskeletal symptoms | 6 | Participants | |
| Number of Participants With On-treatment IFN-associated Flu-like or Musculoskeletal Symptoms | Cohort B: HCV GT-1 or GT-4 | Musculoskeletal symptoms | 21 | Participants | |
| Number of Participants With On-treatment IFN-associated Flu-like or Musculoskeletal Symptoms | Cohort A: HCV GT-2 or GT-3 | Flu-like symptoms | 6 | Participants | |
| Number of Participants With On-treatment IFN-associated Flu-like or Musculoskeletal Symptoms | Cohort B: HCV GT-1 or GT-4 | Flu-like symptoms | 19 | Participants | |
| Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs) | Cohort A: HCV GT-2 or GT-3 | Deaths | 0 | Participants | |
| Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs) | Cohort B: HCV GT-1 or GT-4 | Deaths | 3 | Participants | |
| Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs) | Cohort A: HCV GT-2 or GT-3 | SAEs | 6 | Participants | |
| Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs) | Cohort B: HCV GT-1 or GT-4 | SAEs | 12 | Participants | |
| Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs) | Cohort A: HCV GT-2 or GT-3 | Lambda Dose Reduction | 4 | Participants | |
| Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs) | Cohort B: HCV GT-1 or GT-4 | Lambda Dose Reduction | 19 | Participants | |
| Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs) | Cohort A: HCV GT-2 or GT-3 | Discontinuation due to AEs | 4 | Participants | |
| Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs) | Cohort B: HCV GT-1 or GT-4 | Discontinuation due to AEs | 13 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01866930/results